HPK

HPK
Name	HPK

HPK

HPK is a protein kinase implicated in signal transduction and cellular regulation across multiple taxa. It is studied in contexts ranging from developmental biology to oncology and immunology, attracting investigation by institutions such as Harvard University, Massachusetts Institute of Technology, Stanford University, University of Cambridge, and Max Planck Society. Research on HPK intersects with landmark models and systems including Drosophila melanogaster, Mus musculus, Saccharomyces cerevisiae, Homo sapiens, and Caenorhabditis elegans.

Overview

HPK is a serine/threonine kinase that belongs to kinase families characterized by conserved catalytic domains found in proteins such as MAPK1, AKT1, SRC, ABL1, and CK2A1. The protein is evolutionarily related to components identified in studies by Gregor Mendel, Thomas Hunt Morgan, Seymour Benzer, Francis Crick, and James Watson that elucidated signaling and genetic control. Structural studies have employed methods developed at facilities like European Molecular Biology Laboratory, Brookhaven National Laboratory, Argonne National Laboratory, National Institutes of Health, and Cold Spring Harbor Laboratory to resolve features shared with kinases such as TAK1, MLK3, LKB1, STK11, and CAMK2A.

History

Early descriptions of HPK-like activity emerged from biochemical fractionation work in laboratories led by researchers affiliated with Rockefeller University, University of Oxford, Johns Hopkins University, Yale University, and University of California, San Francisco. Seminal papers published in journals associated with Nature, Science, Cell, Proceedings of the National Academy of Sciences, and EMBO Journal linked HPK to pathways previously mapped for proteins such as RAS, RAF1, MEK1, ERK2, and JNK1. Genetic screens in model organisms by groups at Caltech, Cold Spring Harbor Laboratory, Salk Institute, European Molecular Biology Laboratory, and Wellcome Trust Sanger Institute helped define HPK orthologs and functional domains.

Structure and Mechanism

High-resolution models from laboratories using techniques pioneered at Stanford Synchrotron Radiation Lightsource, Diamond Light Source, European Synchrotron Radiation Facility, Rutherford Appleton Laboratory, and Max Planck Institute (MPI) for Biochemistry reveal a catalytic core homologous to domains in PKA, PKC, IKK, GSK3B, and CHK1. HPK contains regulatory motifs recognized by E3 ligases and adaptors studied in complexes with CUL1, SKP1, BTRC, TRAF6, and NEDD4. Activation mechanisms involve phosphorylation events analogous to those controlling AKT1, SRC, JAK2, TBK1, and IKBKB and are modulated by interactions with scaffold proteins such as GRB2, SOS1, SHC1, 14-3-3, and PICK1.

Biological Functions and Pathways

HPK participates in signaling networks overlapping with paradigms established by Notch signaling pathway, Wnt signaling pathway, TGF-beta signaling pathway, NF-κB pathway, and PI3K-AKT pathway. Functional roles include regulation of processes studied in papers concerning cell cycle checkpoints defined by CDK1, Cyclin B1, p53, RB1, and CHK2; apoptotic cascades involving BCL2, BAX, CASP3, FAS, and TNF; and immune responses coordinated with proteins such as Toll-like receptor 4, CD28, CTLA4, PDCD1, and MHC class I. Cell biological roles have been characterized in systems including neuronal development investigated with BDNF, NGF, TrkB, DLG4, and SYN1.

Clinical Significance and Disease Associations

Aberrant HPK function is associated with pathologies studied at centers including Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center. Links have been drawn between HPK dysregulation and cancers where alterations co-occur with mutations in TP53, KRAS, EGFR, PTEN, and APC; inflammatory diseases involving Rheumatoid Arthritis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Multiple Sclerosis, and Asthma; and neurodegenerative conditions intersecting with Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic Lateral Sclerosis, and Frontotemporal dementia. Genetic association studies have referenced cohorts from UK Biobank, 1000 Genomes Project, Genome-wide Association Study (GWAS), The Cancer Genome Atlas, and ClinVar.

Research Tools and Experimental Methods

Investigations employ reagents and platforms developed by organizations like Addgene, Thermo Fisher Scientific, Sigma-Aldrich, Agilent Technologies, and Illumina. Common approaches include overexpression and knockdown strategies using vectors and systems exemplified by CRISPR-Cas9, RNA interference, lentiviral transduction, adenoviral vectors, and transgenic mice from repositories such as Jackson Laboratory and EMBL-EBI. Biochemical and biophysical assays leverage techniques refined at Broad Institute, European Bioinformatics Institute, ProteomeXchange, Protein Data Bank, and MassIVE for proteomics, phosphoproteomics, cryo-EM, X-ray crystallography, and live-cell imaging often benchmarked against studies of GFP, Luciferase, FRET, FRAP, and BiFC.

Therapeutic Potential and Drug Development

HPK is a target of interest in drug discovery pipelines at pharmaceutical companies like Pfizer, Roche, Novartis, Merck, and GlaxoSmithKline. Small-molecule inhibitors, biologics, and PROTACs have been designed deploying platforms and regulatory frameworks associated with FDA, European Medicines Agency, Investigational New Drug application, Phase I clinical trial, and Phase III clinical trial. Lead optimization applies medicinal chemistry approaches pioneered in collaborations with AstraZeneca, Bayer, Sanofi, Eli Lilly and Company, and Gilead Sciences, and leverages biomarkers and companion diagnostics analogous to those used for HER2, EGFR mutations, BRAF V600E, ALK rearrangements, and BRCA1/2.

Category:Protein kinases